Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | SCN4A | P35499 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1504204 | 0.84 | DRD2 (0.39) | DRD2DRD3PDK1NPC1RAB9A | |
| SCHEMBL29840403 | 0.83 | DRD2 (0.36) | DRD2DRD3PDK1NPC1RAB9A | |
| SCHEMBL23318266 | 0.77 | DRD3 (0.48) | DRD2DRD3PDK1 | |
| SCHEMBL12035209 | 0.72 | DRD2 (0.41) | DRD2DRD3PDK1NPC1RAB9A | |
| SCHEMBL1503760 | 0.71 | DRD2 (0.40) | DRD2DRD3PDK1NPC1RAB9A | |
| SCHEMBL1504035 | 0.70 | DRD2 (0.34) | DRD2DRD3PDK1NPC1RAB9A | |
| SCHEMBL3310859 | 0.69 | DRD2 (0.36) | DRD2DRD3PDK1NPC1RAB9A | |
| SCHEMBL174754 | 0.67 | MTNR1A (0.47) | DRD2DRD3SCN9ASCN3ASCN5A | |
| SCHEMBL23306019 | 0.67 | NPC1 (0.39) | PDK1NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL17385025 | 0.67 | PDK1 (0.73) | PDK1NPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117470-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2023-04-20 | — | — | US | disclosed |
| WO-2021087181-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117470-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS | TLR1, TLR3, TLR9 | DRD2 2381/4885DRD3 1892/4885PDK1 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.